Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children with Disseminated Tuberculosis: Goldilocks

Clinical Infectious Diseases

Volumn 63, Issue , 2016, Pages S102-S109

  Srivastava, Shashikant ^a   Deshpande, Devyani ^a   Pasipanodya, Jotam ^a   Nuermberger, Eric ^b   Swaminathan, Soumya ^c   Gumbo, Tawanda ^a,d  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

combination regimen; dosage design; Monte Carlo experiments; pharmacokinetic variability; target setting

Indexed keywords

FROPENEM; LINEZOLID; MOXIFLOXACIN; BETA LACTAM; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; BONE; CHILD; DRUG EFFICACY; DRUG EXPOSURE; DRUG PENETRATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MENINX; MILIARY TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; PERITONEUM; PRIORITY JOURNAL; AREA UNDER THE CURVE; COMBINATION DRUG THERAPY; COMPUTER SIMULATION; DOSE RESPONSE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MONTE CARLO METHOD; MYCOBACTERIUM TUBERCULOSIS; PRESCHOOL CHILD; STATISTICAL MODEL; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; AREA UNDER CURVE; BETA-LACTAMS; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; HUMANS; INFANT; INFANT, NEWBORN; LINEZOLID; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; MONTE CARLO METHOD; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84994655879     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw483     Document Type: Article

References (58)

1. Lienhardt C, Lönnroth K, Menzies D, et al. Translational research for tuberculosis elimination: priorities, challenges, and actions. PLoS Med 2016;13:e1001965.
2. Nachman S, Ahmed A, Amanullah F, et al. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infect Dis 2015; 15:711-20.
3. Berman S, Kibel MA, Fourie PB, Strebel PM. Childhood tuberculosis and tuberculous meningitis: high incidence rates in the Western Cape of South Africa. Tuber Lung Dis 1992; 73:349-55.
4. van Well GT, Paes BF, Terwee CB, et al. Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in theWestern Cape of South Africa. Pediatrics 2009; 123:e1-8.
5. Shaw JE, Pasipanodya JG, Gumbo T. Meningeal tuberculosis: high long-term mortality despite standard therapy. Medicine (Baltimore) 2010; 89:189-95.
6. Thwaites GE, Bhavnani SM, Chau TT, et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother 2011; 55:3244-53.
7. Pouplin T, Nguyen DB, Pham VT, et al. Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis. BMC Infect Dis 2016; 16:144.
8. Pusch T, Pasipanodya JG, Hall RG, Gumbo T. Therapy duration and long-term outcomes in extra-pulmonary tuberculosis. BMC Infect Dis 2014; 14:115.
9. Shenje J, Ifeoma Adimora-Nweke F, Ross IL, et al. Poor penetration of antibiotics into pericardium in pericardial tuberculosis. EBioMedicine 2015; 2:1640-9.
10. Ge Z,Wang Z,WeiM. Measurement of the concentration of three antituberculosis drugs in the focus of spinal tuberculosis. Eur Spine J 2008; 17:1482-7.
11. Dusthackeer A, Sekar G, Chidambaram S, Kumar V, Mehta P, Swaminathan S. Drug resistance among extrapulmonary TB patients: six years experience from a supranational reference laboratory. Indian J Med Res 2015; 142:568-74.
12. World Health Organization. Global tuberculosis report 2015. Geneva, Switzerland: WHO, 2015.
13. Douste-Blazy P. 4,600 pills over two years - there has to be a better way to treat TB. The Guardian. 24 March 2016. Available at: https://www.theguardian.com/global-development/2016/mar/24/pills-treat-tb-research-multi-drug-resistanttuberculosis. Accessed 20 July 2016.
14. Chiang SS, Khan FA, Milstein MB, et al. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2014; 14:947-57.
15. Seddon JA, Godfrey-Faussett P, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J 2012; 40:1277-86.
16. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204:1951-9.
17. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012; 55:169-77.
18. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208:1464-73.
19. Gumbo T. Biological variability and the emergence of multidrug-resistant tuberculosis. Nat Genet 2013; 45:720-1.
20. Swaminathan S, Pasipanodya J, Ramachandran G, et al. Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests. Clin Infect Dis 2016; 63(suppl 3):S63-74.
21. Chigutsa E, Pasipanodya JG, Visser ME, et al. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother 2015; 59:38-45.
22. Akkerman OW, Odish OF, Bolhuis MS, et al. Pharmacokinetics of bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis. Clin Infect Dis 2016; 62:523-4.
23. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013; 13:27-35.
24. Yogev R, Damle B, Levy G, Nachman S. Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents. Pediatr Infect Dis J 2010; 29:827-30.
25. Sun F, Ruan Q,Wang J, et al. Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis. Antimicrob Agents Chemother 2014; 58:6297-301.
26. Li H, Lu J, Liu J, Zhao Y, Ni X, Zhao S. Linezolid is associated with improved early outcomes of childhood tuberculous meningitis. Pediatr Infect Dis J 2016; 35:607-10.
27. Djukic M, Munz M, Sorgel F, Holzgrabe U, Eiffert H, Nau R. Overton's rule helps to estimate the penetration of anti-infectives into patients' cerebrospinal fluid. Antimicrob Agents Chemother 2012; 56:979-88.
28. Deshpande D, Srivastava S, Nuermberger E, Pasipanodya JG, Swaminathan S, Gumbo T. Concentration-dependent synergy and antagonism of linezolid and moxifloxacin in the treatment of childhood tuberculosis: the dynamic duo. Clin Infect Dis 2016; 63(suppl 3):S88-94.
29. Deshpande D, Srivastava S, Nuermberger E, Pasipanodya JG, Swaminathan S, Gumbo T. A faropenem, linezolid, and moxifloxacin regimen for both drug-susceptible and multidrug-resistant tuberculosis in children: FLAME path on the Milky Way. Clin Infect Dis 2016; 63(suppl 3):S95-101.
30. Deshpande D, Srivastava S, Pasipanodya JG, et al. Linezolid for infants and toddlers with disseminated tuberculosis: first steps. Clin Infect Dis 2016; 63(suppl 3):S80-7.
31. Srivastava S, Deshpande D, Pasipanodya JG, et al. A combination regimen design program based on pharmacodynamic target setting for childhood tuberculosis: design rules for the playground. Clin Infect Dis 2016; 63(suppl 3):S75-9.
32. Hiruy H, Rogers Z, Mbowane C, et al. Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study. J Antimicrob Chemother 2015; 70:1115-23.
33. Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003; 22:S153-7.
34. Thee S, Garcia-Prats AJ, Draper HR, et al. Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. Clin Infect Dis 2015; 60:549-56.
35. Rodriguez JC, Ruiz M, Lopez M, Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002; 20:464-7.
36. Gumbo T, Angulo-Barturen I, Ferrer-Bazaga S. Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia. J Infect Dis 2015; 211(suppl 3):S96-106.
37. Jeena PM, Bishai WR, Pasipanodya JG, Gumbo T. In silico children and the glassmouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis. Antimicrob Agents Chemother 2011; 55:539-45.
38. Gumbo T, Pasipanodya JG, Romero K, Hanna D, Nuermberger E. Forecasting accuracy of the hollow fiber model of tuberculosis for clinical therapeutic outcomes. Clin Infect Dis 2015; 61(suppl 1):S25-31.
39. Pasipanodya JG, Nuermberger E, Romero K, Hanna D, Gumbo T. Systematic analysis of hollow fiber model of tuberculosis experiments. Clin Infect Dis 2015; 61(suppl 1):S10-7.
40. Gumbo T, Pasipanodya JG, Nuermberger E, Romero K, Hanna D. Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm. Clin Infect Dis 2015; 61(suppl 1):S18-24.
41. Metropolis N, Ulam S. The Monte Carlo method. J Am Stat Assoc 1949; 44:335-41.
42. Metropolis N. The beginning of the Monte Carlo method. Los Alamos Sci 1987; Special Issue:125-30.
43. Weinhous MS, Nath R, Schulz RJ. Enhancement of electron beam dose distributions by longitudinal magnetic fields: Monte Carlo simulations and magnet system optimization. Med Phys 1985; 12:598-603.
44. Rogers DW. The role of Monte Carlo simulation of electron transport in radiation dosimetry. Int J Rad Appl Instrum A 1991; 42:965-74.
45. Katz D, D'Argenio DZ. Implementation and evaluation of control strategies for individualizing dosage regimens, with application to the aminoglycoside antibiotics. J Pharmacokinet Biopharm 1986; 14:523-37.
46. Drusano GL, Preston SL, Hardalo C, et al. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 2001; 45:13-22.
47. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190:1642-51.
48. Pasipanodya J, Gumbo T. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother 2011; 55:24-34.
49. Harada Y, Matsumoto T, Tsuji Y, et al. Pharmacokinetic and clinical studies on SY5555 dry syrup in children. Jpn J Antibiot 1995; 48:261-70.
50. Toyonaga Y, Ishihara T, Tezuka T, Nakamura H. Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field. Jpn J Antibiot 1995; 48:71-91.
51. Alffenaar JW, van Altena R, Bokkerink HJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis 2009; 49:1080-2.
52. Stass H, Rink AD, Delesen H, Kubitza D, Vestweber KH. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 2006; 58:693-6.
53. DePestel DD, Peloquin CA, Carver PL. Peritoneal dialysis fluid concentrations of linezolid in the treatment of vancomycin-resistant Enterococcus faecium peritonitis. Pharmacotherapy 2003; 23:1322-6.
54. Arguedas A, Dagan R, Rincon G, et al. Faropenem pharmacokinetics in AOMchildren following oral administration of faropenem medoxomil. In: 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, 2008.
55. Kaushik A, Makkar N, Pandey P, Parrish N, Singh U, Lamichhane G. Carbapenems and rifampin exhibit synergy against Mycobacterium tuberculosis and Mycobacterium abscessus. Antimicrob Agents Chemother 2015; 59:6561-7.
56. Dhar N, Dubee V, Ballell L, et al. Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable beta-lactam antibiotic. Antimicrob Agents Chemother 2015; 59:1308-19.
57. Solapure S, Dinesh N, Shandil R, et al. In vitro and in vivo efficacy of beta-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 2013; 57:2506-10.
58. Yokota T, Azagami S, Abe T, et al. Efficacy and safety of faropenem in pediatric patients with bacterial infectious diseases. Jpn J Antibiot 2008; 61:366-78.